...贫血药甲氧基聚乙二醇促红细胞生成紊一p注射剂上市欧盟批准罗氏公司的一月1次用甲氧基聚乙二醇促红细胞生成素一p注射剂(Mircera)上市,治疗慢性肾病(CKO)引起的贫血。
基于12个网页-相关网页
Roche plans to argue that the public interest would be served if Mircera were allowed on the market, a spokeswoman said.
一个罗氏的发言人讲:罗氏计划争论说如果Mircera不能在市场上销售的话,公众的利益将得不到保护。
Amgen said it was pleased with the verdict and would seek an injunction to prevent Roche from releasing Mircera in the United States.
安进声称满意判决,并将寻求禁令以阻止罗氏在美国发布Mircera。
A federal judge has ruled that Mircera, a Roche anemia drug that would compete with Amgen's Epogen and Aranesp, violates an Amgen patent.
一次联邦审判认定Mircera,一个罗氏生产的用于同安进的Epogen和Aranesp竞争的药物,触犯了安进的专利权。
应用推荐